Proteomic analysis of Intercept-treated platelets.
In the past decades, transfusion medicine has been driven by the quest for increased safety against transfusion-transmitted infections, mainly by better donor selection and by the development of improved serological and nucleic-acid-based screening assays. Recently, pathogen reduction technologies became available and started to be implemented in several countries, with the primary goal to fight against bacterial contamination of blood products, a rare but dramatic event against which there was no definitive measure. Though pathogen reduction technologies represent a quantum leap in transfusion safety, the biomedical efficacy of platelet concentrates (PCs) treated with various pathogen reduction techniques has been recently questioned by clinical studies. Here, a gel-based proteomic analysis of PCs (n=5), Intercept-treated or untreated, from pooled buffy-coat (10 donors per PC) at Days 1, 2 and 8, shows that the Intercept process that is the most widespread pathogen reduction technique to date, has relatively low impact on the proteome of treated platelets: the process induces modifications of DJ-1 protein, glutaredoxin 5, and G(i)alpha 2 protein. As for the impact of storage, chloride intracellular channel protein 4 (CLIC4) and actin increased independently of Intercept treatment during storage. Whereas alteration of the DJ-1 protein and glutaredoxin 5 points out an oxidative stress-associated lesion, modification of G(i)alpha2 directly connects a possible Intercept-associated lesion to haemostatic properties of Intercept-treated platelets. This article is part of a Special Issue entitled: Integrated omics.
Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland.
Michel
M
Prudent
David
D
Crettaz
Julien
J
Delobel
Jean-Daniel
JD
Tissot
Niels
N
Lion
D058621:Blood Buffy Coat / Q000166:cytology / Q000378:metabolism / Q000382:microbiology; D001792:Blood Platelets / Q000166:cytology / Q000378:metabolism* / Q000382:microbiology; D001798:Blood Proteins / Q000378:metabolism*; D005260:Female; D011564:Furocoumarins / Q000494:pharmacology*; D006801:Humans; D008297:Male; D050296:Microbial Viability / Q000187:drug effects; D017319:Photosensitizing Agents / Q000494:pharmacology*; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics; D013242:Sterilization / Q000379:methods*
D001798:Blood Proteins; D011564:Furocoumarins; D017319:Photosensitizing Agents; D020543:Proteome